Tesamorelin

Tesamorelin

$75.00 – $120.00

Tesamorelin is a synthetic peptide that acts as a growth hormone-releasing factor (GHRF) analogue. By stimulating the release of growth hormone (GH) from the pituitary gland, Tesamorelin plays a key role in regulating several metabolic functions, including fat metabolism, protein synthesis, and tissue regeneration. It has been primarily researched for its potential effects on reducing visceral fat, particularly in individuals with HIV-associated lipodystrophy, though its broader applications in metabolic and aging research are of significant interest.

Tesamorelin has been the subject of numerous studies investigating its impact on fat distribution, muscle mass, and metabolic regulation. Researchers also use Tesamorelin to explore the broader role of GH in age-related conditions, such as sarcopenia (muscle wasting) and insulin resistance. This product, in its 20mg form, is manufactured under rigorous quality standards and is designed for research purposes only.

0% 1 - 4 $75.00
10% 5 - 9 $67.50
20% 10 + $60.00
  • Free shipping on orders over $200
  • Discounts: Calculated in cart.

Description

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that consists of a chain of 44 amino acids. Its primary mechanism of action involves stimulating the anterior pituitary gland to release endogenous growth hormone (GH). The released GH subsequently stimulates the production of insulin-like growth factor 1 (IGF-1), which plays a vital role in muscle growth, tissue repair, and the regulation of various metabolic functions.

Originally developed for the treatment of HIV-associated lipodystrophy—a condition characterized by abnormal fat distribution—Tesamorelin has also been the subject of research exploring its potential to reduce visceral fat. Visceral fat is known to contribute to metabolic disorders, such as insulin resistance, cardiovascular disease, and type 2 diabetes. Tesamorelin’s ability to target visceral fat has made it a valuable peptide in studies of obesity and metabolic disease.

In addition to its fat-reducing effects, Tesamorelin has been studied for its potential to enhance muscle mass and improve overall metabolic health. It is believed that by stimulating GH and IGF-1 release, Tesamorelin can support protein synthesis and cellular regeneration, making it a promising tool for research into sarcopenia and muscle wasting conditions.

Tesamorelin has also gained attention in the field of aging research. As GH levels naturally decline with age, Tesamorelin has been explored for its potential to restore GH function and counteract age-related declines in muscle mass, bone density, and metabolic function. By stimulating the release of GH, Tesamorelin could potentially help in mitigating some of the effects of aging, such as decreased muscle strength, increased fat accumulation, and metabolic inefficiency.

Furthermore, Tesamorelin has been used in research involving the hypothalamic-pituitary-gonadal axis, where it helps to investigate hormonal feedback loops and the body’s response to various stimuli. Its effects on metabolic and regenerative processes, as well as its potential to support healthy aging and fat metabolism, make it an essential peptide in cutting-edge scientific research.

This 20mg formulation of Tesamorelin is designed for research-grade studies and is carefully manufactured to ensure the highest standards of purity and consistency. It should be reconstituted with sterile water and used in controlled laboratory settings for in vitro or in vivo experiments.

Note: This product is intended for research purposes only. It is not for human or veterinary use.

Research

Tesamorelin has gained significant attention in both clinical and preclinical research due to its ability to stimulate growth hormone (GH) release, particularly for the reduction of visceral fat and the enhancement of muscle mass. While it was initially developed to address HIV-associated lipodystrophy—a condition marked by abnormal fat deposits—researchers have since explored its broader applications in metabolic health, obesity, and aging.

One of the primary areas of research has been Tesamorelin’s effect on visceral fat. Visceral fat, which is fat stored around internal organs, is a significant risk factor for cardiovascular diseases, insulin resistance, and type 2 diabetes. Several clinical studies have shown that Tesamorelin can reduce visceral fat, potentially improving metabolic function and reducing the risk of developing obesity-related diseases. This has made Tesamorelin a promising candidate in the development of therapies for metabolic disorders.

In addition to its effects on fat metabolism, Tesamorelin is being researched for its ability to enhance muscle mass and tissue repair. The peptide stimulates the release of growth hormone, which in turn promotes the production of IGF-1. IGF-1 is known to play a vital role in muscle growth, repair, and protein synthesis, making Tesamorelin an important tool in studies involving muscle wasting and regenerative medicine. Its potential applications in sarcopenia, age-related muscle loss, and muscle regeneration after injury are areas of active investigation.

The peptide’s effects on the aging process have also been a topic of interest. As the body ages, natural growth hormone production decreases, leading to a decline in muscle mass, bone density, and metabolic efficiency. Tesamorelin has been studied as a means of counteracting these age-related declines by stimulating GH release. Research on this front suggests that Tesamorelin could play a role in preserving muscle function, improving bone health, and enhancing overall metabolic rate in older individuals.

Additionally, Tesamorelin has been explored in relation to its impact on insulin sensitivity and fat distribution. Its effects on these metabolic factors are crucial for understanding its potential use in treating obesity, metabolic syndrome, and other related disorders. Through its action on GH and IGF-1 pathways, Tesamorelin offers valuable insights into how the body regulates fat metabolism and muscle growth.

In summary, Tesamorelin continues to be an important peptide for research into metabolic health, aging, and muscle regeneration. Its ability to stimulate growth hormone release makes it a versatile tool in scientific studies aimed at understanding and potentially mitigating the effects of aging, obesity, and muscle-related diseases.

For research use only. Not intended for human or animal use.

References:

  1. Clinical Review Report: Tesamorelin (Egrifta). Ottawa (ON): Canadian Agency for Drugs and Technologies in Health, 2016.
  2. A. Mangili, J. Falutz, J.-C. Mamputu, M. Stepanians, and B. Hayward, “Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat,” PloS One, vol. 10, no. 10, p. e0140358, 2015. [PubMed]
  3. J. Falutz et al., “Metabolic effects of a growth hormone-releasing factor in patients with HIV,” N. Engl. J. Med., vol. 357, no. 23, pp. 2359–2370, Dec. 2007. [NEJM]
  4. T. L. Stanley et al., “Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin,” Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am., vol. 54, no. 11, pp. 1642–1651, Jun. 2012. [PubMed]
  5. V. Rochira and G. Guaraldi, “Growth hormone deficiency and human immunodeficiency virus,” Best Pract. Res. Clin. Endocrinol. Metab., vol. 31, no. 1, pp. 91–111, 2017. [PubMed]
  6. S. H. Tuffaha et al., “Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury,” Expert Opin. Ther. Targets, vol. 20, no. 10, pp. 1259–1265, Oct. 2016. [PubMed]
  7. S. D. Friedman et al., “Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging,” JAMA Neurol., vol. 70, no. 7, pp. 883–890, Jul. 2013. [PubMed]

Related products

Shopping Cart
Scroll to Top
0